文献速递细胞病理与分子病理

分子肿瘤检测实验室CAP认证检查中最常见缺陷及改进机会

Most Frequently Cited Accreditation Inspection Deficiencies for Clinical Molecular Oncology Testing Laboratories and Opportunities for Improvement.
PubMed 文献 · Arch Pathol Lab Med · 2022-01-01

美国病理学家学会(CAP)分子肿瘤委员会回顾2018-2020年两年间接受CAP认证检查的分子肿瘤检测实验室数据与检查员意见,识别最常见缺陷。422家实验室中159家(37.7%)无分子肿瘤相关缺陷;All Common与Molecular Pathology清单分别有364和305项缺陷,合规率98.8%和99.6%。结论认为分子肿瘤实验室整体合规性优秀,并评估了改进机会。

要点

  • 422家受检分子肿瘤实验室中159家(37.7%)无分子肿瘤相关缺陷。
  • All Common清单缺陷364项、合规率98.8%;Molecular Pathology清单缺陷305项、合规率99.6%。
  • COM清单缺陷多集中于分析检测阶段,MOL清单缺陷在检验前、中、后三阶段分布更均匀。

核心结论

  • 分子肿瘤实验室在支持高质量检测结果的相关实践上表现出优秀合规性。
  • 该综述评估了实验室改进合规性与分子肿瘤检测质量的机会。

研究设计与样本

  • CAP分子肿瘤委员会(MOC)回顾CAP在2018-2020年两年间检查的分子肿瘤检测实验室数据及检查员意见。
  • 共422家分子肿瘤实验室接受认证检查。
  • MOC参与维护分子病理学检查清单。

主要发现

  • 422家实验室中159家(37.7%)未被引用任何分子肿瘤相关缺陷。
  • All Common(COM)清单共364项缺陷,合规率98.8%。
  • Molecular Pathology(MOL)清单共305项缺陷,合规率99.6%。
  • COM清单缺陷最常关联分析检测阶段。
  • MOL清单缺陷在检验前、分析、检验后阶段分布更均匀。

临床怎么用

  • 实验室可参照最常见被引用缺陷类型自查,重点加强分析检测阶段的COM清单合规。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: The College of American Pathologists (CAP), a laboratory accreditation organization with deemed status under the Clinical Laboratories Improvement Amendments of 1988 administers accreditation checklists. Checklists are used by laboratories to ensure regulatory compliance. Peer-level laboratory professionals audit laboratory records during inspections to assess compliance. OBJECTIVE.—: To identify the most frequently cited deficiencies for molecular oncology laboratories undergoing CAP accreditation inspections and describe laboratory improvement opportunities. DESIGN.—: The CAP Molecular Oncology Committee (MOC), which is involved in maintaining the Molecular Pathology checklist, reviewed data and inspector comments associated with the most frequently observed citations related to molecular oncology testing from laboratories inspected by the CAP during a 2-year period (2018-2020). RESULTS.—: Of 422 molecular oncology laboratories that underwent accreditation inspections, 159 (37.7%) were not cited for any molecular oncology-related deficiencies. For the All Common (COM) and Molecular Pathology checklists, there were 364 and 305 deficiencies, corresponding to compliance rates of 98.8% and 99.6%, respectively. The most frequently cited deficiencies are described. The COM checklist deficiencies were associated most often with the analytic testing phase; the MOL checklist deficiencies were more evenly distributed across the preanalytic, analytic, and postanalytic phases of testing. CONCLUSIONS.—: Molecular oncology laboratories demonstrated excellent compliance with practices that support high-quality results for patients and the health care providers who use those test results in patient management. This review includes a critical assessment of opportunities for laboratories to improve compliance and molecular oncology testing quality.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Sidiropoulos N, Daley SK, Briggs M, et al. Most Frequently Cited Accreditation Inspection Deficiencies for Clinical Molecular Oncology Testing Laboratories and Opportunities for Improvement. Arch Pathol Lab Med. 2022. PMID: 35438717. doi:10.5858/arpa.2021-0448-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。